You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
龍虎榜數據一覽 | 通富微電當日淨買入額最多,長春高新獲3機構買入3.33億元

A股指數集體收漲,兩市3400股上漲,1230股下跌,成交額不足萬億,但較上個交易日放量960億,市場情緒及賺錢效應相比昨日好轉。題材概念整體表現活躍,科技股全面爆發,半導體板塊狂掀漲停潮,一體壓鑄概念逆勢大跌。

今日,龍虎榜淨買入額榜前三為通富微電、時代電氣、廣立微,分別為2.21億元、2.14億元、1.57億元。淨賣出金額居前三的個股分別是秦川機牀、巨輪智能、贛能股份,分別為1.27億元、1.15億元、1.01億元。

龍虎榜中涉及機構專用席位的個股中,當日淨買入額前三為長春高新、北方華創、海利爾,分別為2.69億元、1.77億元、8764.36萬元。

個股關注點:

長春高新:

1、水痘疫苗龍頭;子公司百克生物主打產品包括水痘疫苗、狂犬疫苗和鼻噴流感疫苗,其中水痘疫苗市佔率第一、凍幹鼻噴流感疫苗作為國內唯一獲批的鼻噴流感減毒活疫苗已上市銷售;研發方面,百克生物人用狂犬病疫苗(Vero細胞)凍幹劑型產品Ⅲ期臨牀試驗已基本完成,帶狀皰疹減毒活疫苗產品Ⅲ期臨牀試驗已進入尾聲,吸附無細胞百白破(三組分)聯合疫苗已經獲批臨牀;20年基因工程收入72.36億元,佔比84.36%;

2、子公司長春百克擁有水痘疫苗-預防水痘,市佔率32%(第一);孫公司吉林邁豐生物主要產品是人用狂犬病疫苗;子公司百克藥業主要研究中國流行株預防用艾滋病疫苗;創新藥方面,偽人蔘皂苷GQ處於臨牀II期,艾塞那肽申報待批;

3、2018年促卵泡素作為最重要的輔助生殖用藥之一,公司市場佔比約30%。

北方華創:

1、國內稀缺平台型泛半導體設備供應商,PVD機台是全球前三CIS封裝企業首選;大基金持股7.46%;

2、公司自主研發的12寸單片銅互連清洗機進入中芯國際B2芯片生產線;

3、國產半導體設備龍頭;公司是國內主流高端電子工藝裝備供應商,刻蝕機、PVD、CVD、氧化/擴散爐、退火爐、清洗機等產品在集成電路及泛半導體領域實現量產應用;21年電子工藝裝備收入79.49億元,營收佔比82.08%。

海利爾:

1、主營農藥製劑、農藥中間體、農藥原藥和水溶性肥料的研發、生產和銷售,產品包括吡蟲啉和啶蟲脒等,公司已制定了多個針對草地貪夜蛾的產品解決方案;

2、農藥製劑、原藥和中間體一體化生產企業;主營農藥製劑、農藥中間體、農藥原藥,其中農藥製劑主要涵蓋殺蟲劑、殺菌劑、除草劑等系列品種,農藥原藥主要是吡蟲啉、啶蟲脒、吡唑醚菌酯、甲維鹽、噻蟲胺和丙硫菌唑等,農藥中間體為二氯;20年農藥收入31.44億元,營收佔比97.42%。

泰嘉股份8月3日,泰嘉股份發佈重大資產重組方案顯示,公司將控股鉑泰電子,將鉑泰電子納入合併報表範圍。據悉,鉑泰電子目前持有知名消費電子電源生產商雅達電子100%股權。此次增資並表將大幅提升泰嘉股份的收入體量,並大幅推進其在消費電子領域的戰略佈局進程。

機構重點關注個股:

長春高新:3機構買入3.33億元,1機構賣出6438.05萬元

北方華創:2機構買入2.81億元,1機構賣出1.04億元

海利爾:3機構買入1.35億元,1機構賣出4777.23萬元

泰嘉股份:4機構買入1億元,2機構賣出4115.15萬元

龍虎榜中,滬股通專用席位個股詳情:

龍虎榜中,深股通專用席位個股詳情:

遊資操作動向:

歡樂海岸:淨買入N江波龍2309.91萬元,淨買入青島雙星1154.21萬元

東北猛男:淨賣出新勁剛2239.25萬元

成都幫:淨賣出通威富電1025.32萬元,淨買入聚賽龍674.81萬元

趙老哥:淨買入智立方1781.24萬元,淨買入晶方科技2683.90萬元,淨賣出精倫電子、冰山冷熱、天沃科技,分別為1291.55萬元、1327.11萬元、2398.28萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account